PRI-002

DRUG2 trials

Sponsors

Prinnovation GmbH, PRInnovation GmbH

Conditions

Alzheimer's Disease, Early OnsetAlzheimer's diseaseMild Cognitive Impairment Due to Alzheimer's Disease

Phase 2

Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alzheimer’s disease (AD)

RecruitingCTIS2022-503148-41-00

Prinnovation GmbHAlzheimer's disease

Start: 2023-12-01Target: 339Updated: 2026-01-12

Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)

CompletedNCT06182085

PRInnovation GmbHAlzheimer's Disease, Early Onset, Mild Cognitive Impairment Due to Alzheimer's Disease

Start: 2024-02-15End: 2026-07-02Updated: 2026-07-10

Related Papers

Anti‐oligomeric PRI‐002 does not cause ARIA‐E in an ongoing Phase 2 trial

Alzheimer s & Dementia2025-12-01

PRImus‐AD study: Design of the phase 2 study treating patients with MCI or mild dementia due to Alzheimer’s disease (AD) with the orally available PRI‐002

Alzheimer s & Dementia2025-12-01